Phase 3 Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had an acute (sudden-onset) stroke caused by a blocked small blood vessel in the brain, confirmed by MRI, within the last 72 hours
- People whose stroke symptoms have noticeably worsened — either a significant drop in overall neurological function or worsening of movement or coordination — as confirmed by the treating neurologist
- People where this worsening happened less than 6 hours before being enrolled in the trial
- People aged 18 years or older
- Women who are able to become pregnant and are using an accepted form of contraception (such as an IUD, hormonal contraception, sterilisation, a vasectomised partner, or complete abstinence)
- People who are covered by a health insurance system
Who may not be able to join:
- People who had significant disability before the stroke (confirm with trial site)
- People who cannot have an MRI brain scan
- People considered at high risk of bleeding in the brain, including those with 10 or more small old bleeds on MRI, a certain type of iron deposit on the brain surface, bleeding already present in the current stroke, any previous brain bleed, or a blood vessel abnormality or tumour in the brain that could bleed
- People who received clot-dissolving treatment (thrombolysis) through a drip within the last 24 hours
- People who will need blood-thinning medication (anticoagulants) within the first 7 days after joining the trial
- People with blood pressure that is too high at the time of enrolment (systolic above 180 mmHg or mean arterial pressure at or above 110 mmHg)
- People whose stroke is caused by a large artery blockage or narrowing, an artery tear (dissection), or a clot travelling from the heart
- People taking certain medications that interact with norepinephrine, including some antidepressants (tricyclics), certain Parkinson's medications (entacapone), or a class of medicines called monoamine oxidase inhibitors (including linezolid)
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pauline RENOU, University Hospital, Bordeaux
Phone: 05-56-79-55-20
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
modified Rankin Scale (mRS); modified Rankin Scale (mRS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.